Modlin Nadav Liam, McPhee Tyler, Zazon Nira, Sarang Maria, Hignett Rebecca, Pick Susannah, Cleare Anthony, Williamson Victoria, Rucker James
The Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
South London and Maudsley NHS Foundation Trust, Maudsley Hospital, Denmark Hill, London, United Kingdom.
Psychedelic Med (New Rochelle). 2025 Feb 27;3(1):19-30. doi: 10.1089/psymed.2024.0027. eCollection 2025 Mar.
Psychedelics such as psilocybin, lysergic acid diethylamide, and 3,4-methylenedioxymethamphetamine are increasingly recognized for their potential therapeutic benefits in treating complex and chronic mental health conditions. Growing public interest in psychedelics may drive increased consumption outside of medically supervised clinical trials. Correspondingly, legality issues and potential risks of unregulated use underscore the need for structured aftercare support, including psychedelic integration groups, to reduce harm potential.
This study utilized a cross-sectional, observational, online, anonymous survey with 65 participants who used psychedelics and attended psychedelic integration groups. Participants provided qualitative data on their experiences via open-ended questions. Employing a deliberate analytic strategy, responses were subsequently analyzed using thematic analysis to identify key patterns and themes.
Three primary themes and associated subthemes emerged from the data: (1) reasons for attending psychedelic integration groups, (2) utility of psychedelic integration groups, and (3) adverse factors influencing participants' experience of the group.
The study underscores the therapeutic potential of psychedelic integration groups in providing essential community support and facilitating the processing of psychedelic experiences. However, it also highlights significant challenges, such as managing group dynamics and ensuring facilitators are adequately trained. These findings suggest that while integration groups can mitigate some risks associated with psychedelic use, research is needed to optimize their structure and effectiveness. Specifically, future studies should explore the development of standardized protocols and facilitator training programs to enhance the safety and efficacy of these groups. This research is crucial to inform policy and practice, ensuring that individuals seeking integration support and aftercare following psychedelic use have access to well-designed and delivered interventions.
诸如裸盖菇素、麦角酸二乙酰胺和3,4-亚甲基二氧甲基苯丙胺等迷幻剂,因其在治疗复杂和慢性心理健康状况方面的潜在治疗益处而日益受到认可。公众对迷幻剂的兴趣日益浓厚,这可能导致在医学监督的临床试验之外的消费增加。相应地,合法性问题和不受监管使用的潜在风险凸显了结构化后续护理支持的必要性,包括迷幻剂整合小组,以降低潜在危害。
本研究采用横断面、观察性、在线、匿名调查,共有65名使用迷幻剂并参加迷幻剂整合小组的参与者。参与者通过开放式问题提供了关于他们经历的定性数据。随后采用深思熟虑的分析策略,使用主题分析对回答进行分析,以识别关键模式和主题。
数据中出现了三个主要主题及相关子主题:(1)参加迷幻剂整合小组的原因,(2)迷幻剂整合小组的效用,(3)影响参与者小组体验的不利因素。
该研究强调了迷幻剂整合小组在提供基本社区支持和促进迷幻剂体验处理方面的治疗潜力。然而,它也突出了重大挑战,如管理小组动态和确保 facilitators 接受充分培训。这些发现表明,虽然整合小组可以减轻与迷幻剂使用相关的一些风险,但需要进行研究以优化其结构和有效性。具体而言,未来的研究应探索制定标准化方案和 facilitator 培训计划,以提高这些小组的安全性和有效性。这项研究对于为政策和实践提供信息至关重要,确保在使用迷幻剂后寻求整合支持和后续护理的个人能够获得精心设计和实施的干预措施。